Multiple Myeloma | Specialty

CAR T Explodes on the Scene in Heavily Pretreated Multiple Myeloma

February 24th 2021

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Dr. Nooka on the Utility of BCMA as a Target in Multiple Myeloma

February 23rd 2021

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Dr. Schmidt on the Safety and Efficacy of Teclistamab in Multiple Myeloma

February 22nd 2021

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

Dr. Callander on the Potential Future of Belantamab Mafodotin in Multiple Myeloma

February 19th 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Novel Additions Require Nuanced Treatment Selection in Relapsed/Refractory Myeloma

February 19th 2021

Parameswaran Hari, MD, MRCP, discusses single-agent and combination strategies that have recently been introduced to the relapsed/refractory multiple myeloma setting and the nuances to utilizing them in clinical practice.

CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma

February 18th 2021

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Using MRD to Inform Treatment Decisions in Transplant-Eligible Myeloma

February 18th 2021

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision making, and future directions for research.

Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma

February 17th 2021

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Dr. Hari on the Role of Carfilzomib, Pomalidomide, and Dexamethasone in R/R Myeloma

February 17th 2021

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

x